Sector News

Lundbeck’s CEO resigns after breach of company rules

November 24, 2014
Life sciences
(Reuters) – Danish pharmaceutical company Lundbeck’s chief executive Ulf Wiinberg has resigned because of a breach in the company’s code of conduct relating to shares he received in a biotech group.
 
Lundbeck said in 2013, Wiinberg had not obtained prior approval from the board to receive shares in biotech company Stratified Medical from its founder.
 
Lundbeck said in a statement on Monday that the shares in question were in a company in which Lundbeck later invested around 19 million Danish crowns ($3.2 million).
 
Wiinberg apologised for these events, which he said were unintentional on his part and that he had told chairman Håkan Björklund about them himself.
 
“Based on these events, I have found it in both parties’ best interests that I resign from my position today,” Wiinberg said.
 
Lundbeck’s shares fell as much as 9.8 percent just after the stock market opened in Copenhagen. By 09:24 GMT the shares were 1.3 percent lower at 124.70 crowns while Copenhagen main index was up 0.7 percent.
 
Lundbeck said a search for a replacement for Wiinberg would begin immediately.
 
Soren Lontoft, analyst from Sydbank, said Wiinberg had been important for Lundbeck’s development from a company with one major product, a depression treatment, to one with several treatments for the central nervous system.
 
“The timing is really bad for Lundbeck facing expiring patents for key products, and with launches and upcoming approvals for new products in the next couple of years,” Lontoft said.
 
Lundbeck chairman Bjorklund said in the statement that although Wiinberg had acknowledged and apologised for his erroneous actions, this did not change the fact that Lundbeck had a clear and unmistakable code of conduct for all employees.
 
Wiinberg’s pay in 2013 was DKK 16.7 million, according to the company’s annual report.
(1 US dollar = 5.9996 Danish crown)
 
By Ole Mikkelsen (Additional reporting by Annabella Pultz Nielsen. Editing by Jane Merriman)

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach